HLS Therapeutics Inc faced a challenging trading day, with its stock price declining significantly.
In yesterday's trading session, HLS Therapeutics Inc (HLS.TO) saw a notable drop of 2.62%, closing at CA$4.09. This decline has raised concerns among investors about the company's short-term performance, especially in light of its recent financial results.
Investor takeaway: Investors should closely monitor HLS Therapeutics Inc for any further developments, particularly regarding its recent financial performance and market conditions.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$126.52M
52W high
$5.64
52W low
$3.56
1W change
+5.68%
Beta
0.76
Analyst Price Targets
Based on analyst covering HLS · as of Oct 12, 2026
Wall Street analysts forecast HLS stock price to rise 83.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.51
+83.6% Upside
Previously C$7.49 on Oct 9, 2026
Current Price
C$4.09
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
48.6%
Annualized
90-Day Vol
38.6%
Annualized
Trend (90d)
-11.1%
Annualized drift
90d Mean
C$3.93
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.04 | C$3.41 – C$4.77 |
| 60 trading days | C$3.98 | C$3.14 – C$5.05 |
| 90 trading days | C$3.93 | C$2.94 – C$5.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
HLS Therapeutics Inc's market cap stands at CA$126.5 million.
With a market cap of CA$126.5 million, HLS Therapeutics Inc's stock performance is crucial for investor confidence and future funding opportunities.
Bull case
The company reported a 3.5% increase in revenue year-over-year in its latest financial results, suggesting potential growth in its cardiovascular portfolio.
Bear case
Despite the revenue growth, HLS's profit margin remains negative at -15.24%. This raises concerns about its overall financial health and sustainability.
Recent Financial Performance
Advertisement
HLS Therapeutics recently reported a 3.5% increase in revenue year-over-year for Q2 2026, totaling CA$14.7 million. However, the ongoing negative profit margin of -15.24% raises doubts about the company's ability to maintain profitability in the long run. Investors should keep an eye on future earnings reports for signs of improvement.
Market Reaction
The decline in HLS's stock price reflects investor concerns about its financial health. Despite the recent revenue growth, the negative profit margin indicates challenges in converting sales into profit. This situation could lead to increased scrutiny from analysts and investors alike.
Looking Ahead
As HLS Therapeutics continues to navigate its financial landscape, investors should stay alert. The company's recent approval of NILEMDO™ and its new credit agreement may offer some optimism, but the market's reaction to yesterday's decline suggests that confidence may be wavering. Stakeholders should watch for upcoming announcements that could impact stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
